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Background: Probiotic administration has been proposed for the
prevention and treatment of speciﬁc allergic manifestations such as
eczema, rhinitis, gastrointestinal allergy, food allergy, and asthma.
However, published statements and scientiﬁc opinions disagree
about the clinical usefulness.
Objective: A World Allergy Organization Special Committee on
Food Allergy and Nutrition review of the evidence regarding the use
of probiotics for the prevention and treatment of allergy.
Methods: A qualitative and narrative review of the literature on
probiotic treatment of allergic disease was carried out to address
the diversity and variable quality of relevant studies. This
variability precluded systematization, and an expert panel group
discussion method was used to evaluate the literature. In the absence
of systematic reviews of treatment, meta-analyses of prevention
studies were used to provide data in support of probiotic applications.
Results: Despite the plethora of literature, probiotic research is still
in its infancy. There is a need for basic microbiology research on the
resident human microbiota. Mechanistic studies from biology,
immunology, and genetics are needed before we can claim to
harness the potential of immune modulatory effects of microbiota.
Meanwhile, clinicians must take a step back and try to link disease
state with alterations of the microbiota through well-controlled long-
term studies to identify clinical indications.
Conclusions: Probiotics do not have an established role in the
prevention or treatment of allergy. No single probiotic supplement
or class of supplements has been demonstrated to efﬁciently
inﬂuence the course of any allergic manifestation or long-term
disease or to be sufﬁcient to do so. Further epidemiologic,
immunologic, microbiologic, genetic, and clinical studies are
necessary to determine whether probiotic supplements will be
useful in preventing allergy. Until then, supplementation with
probiotics remains empirical in allergy medicine. In the future,
basic research should focus on homoeostatic studies, and clinical
research should focus on preventive medicine applications, not
only in allergy. Collaborations between allergo-immunologists
and microbiologists in basic research and a multidisciplinary
approach in clinical research are likely to be the most fruitful.
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INTRODUCTION
Humans have evolved to establish and maintain relative
equilibrium with the dynamic and evolving microbial world.
The body, inside and out, is cloaked with microbes that are
likelier to be friends than enemies. Hence, the epidermal
surface, respiratory tract, vagina, and large bowel are homes to
biodiverse microbial communities (microbiota) containing
mostly nonpathogenic bacterial species.1–3 These bacteria are
commonly referred to as commensals or symbionts because
they form long-lasting interactive associations with their hosts.
Inside the womb, the fetus lives in a sterile environment. How-
ever, during and immediately after birth, body surfaces, includ-
ing the gastrointestinal tract, are adventitiously inoculated with
bacteria of environmental and maternal origin. A regulated and
predictable succession of bacterial groups is soon established.
Those of the large-bowel microbiota are especially well stud-
ied4–6; less is known about the microbiota of the small intestine,
airway, and skin. Alone among mammalian species, the large-
bowel bacterial community of human infants is dominated
during the ﬁrst months of life by members of the genus Biﬁ-
dobacterium. These bacteria are particularly capable of grow-
ing on milk oligosaccharides. The composition of the gut
microbiota becomes more complex as the milk diet is supple-
mented with solid food and changes markedly after cessation of
breastfeeding.5 During early life, while immunological germi-
nal foci develop in the bowel mucosa, the bowels of infants
undergo a succession of changes with respect to the composi-
tion of the microbiota. Looked at immunologically, this suc-
cession must also represent a changing antigenic load of
undeterminable size associated with the mass of bacterial
organisms. Although most knowledge of the human microbiota
is derived from studies of the bowel, similar changes probably
occur in other parts of the body colonized by commensals.
These changes may be as substantial as events in the bowel
in forming the possible relationship between microbial expo-
sure and allergies (see Establishing the Link Between Probiotic
Administration and Disease Treatment). Immune homeostasis
in the gut, sometimes called immune privilege, develops as
a relationship is established between the intestinal microbiota,
luminal antigens, and the epithelial barrier.7 Tolerance to food
antigens seems to require such a consortial relationship. Allergy
may develop due to a failure to establish immune tolerance to
nonharmful dietary proteins or to a loss of balance between
immune suppression and sensitization. Many human genes
are known to play some role in susceptibility to allergy
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development, but many environmental factors have also been
implicated. As clinicians and scientists study whether inter-
ventions, such as the introduction of probiotic bacterial species,
may be used to either initiate tolerance or restore a balance
of tolerance, the complexity of the task is becoming evident.
It seems essential to consider how each compartment of the
body is affected by different microorganisms, what stage in
the disease process is appropriate for intervention, and what
dose of microorganism should be applied and for how
long.8–10
Take-home message:
• There are probably hundreds of explanations for the
apparent surge in allergic disease in afﬂuent countries
over the past 60 years.11–14
• Ethnicity and maternal diet, different hygiene standards
and obstetric practices, and the frequency of use of anti-
biotics may account for some of the observed differences.
• Changes in lifestyle with a marked impact on exposure
to bacteria and differences in bowel microbiota of
infants born in countries with low or high prevalence
of allergies have been most frequently cited.15,16
• However, differences in patterns and abundance of
microbes and parasitic worms between today and 60
years ago are not testable.
• The connection between the composition of the microbiota
in early life, the programming of the immune system in
terms of later response to environmental allergens, and pre-
disposition of the child to allergies are the research topics
we should focus on.17–21
DEFINITIONS AND OBJECTIVES
For the purposes of this document, the following
deﬁnitions will be used:
• Probiotics: microorganisms that “confer a health beneﬁt
on the host.”22 Hereafter, they will be deﬁned as pro-
prietary formulations of speciﬁc microorganisms (genus,
species, and strain) and quantiﬁed populations of live
bacteria that can be legally prescribed by physicians.
• Treatment: intervention targeting primary, secondary, or
tertiary prevention; temporary relief; or cure.
• Supplementation: intervention targeting add-on, or adju-
vant, therapy aimed at interfering with allergic mecha-
nisms or homoeostatic processes, for efﬁcient and
sufﬁcient treatment (as deﬁned above).
• Microbiota: a bacterial community inhabiting a particular
body site
• Commensals (or symbionts): the members of the
microbiota.
• Metagenome: the collective genomes of the microbiota
(sometimes this is alluded to as “microbiome,” an equiv-
ocal term that will not be used in this document).
The aim of the present document was to examine the
claims that probiotic supplements can be used for the treatment
of allergic disease according to the above deﬁnitions.
EPISTEMOLOGY
The Translation From Prevention
to Treatment
Probiotics, originally conceived for treatment of gas-
trointestinal diseases and later applied to allergy prevention,
are increasingly proposed for the treatment of allergic
disease.23–26 This is a matter of concern for allergists because,
despite the extensive literature on probiotics, the translation
from possible prevention effects to therapeutic efﬁcacy
remains to be demonstrated. At issue are the limited number
and quality of clinical trials and their reproducibility,27 and
several meta-analyses have refrained from recommending
probiotics as therapeutic agents. This situation is likely to
continue as long as appropriate indications, patient selection,
strain-speciﬁc effects, doses, mechanisms of action, optimal
initiation and duration of treatment, adequate follow-ups,
product reliability, and availability have not been clearly
established outside research settings.
The Basic Assumption Behind Treatment is
Based on Two Working Hypotheses
The hygiene hypothesis and the microbial origin of
allergic disease hypothesis (see Hygiene Hypothesis, Micro-
bial Origin of Allergic Disease Hypothesis, and Probiotics)
have both been proposed to explain the epidemic of allergic
disease. However, the question is whether there is sufﬁcient
proof from basic research to support or refute claims of
clinical efﬁcacy of speciﬁc probiotic interventions to modify
the individual host response. No clear “biological conductor”
or mechanism orchestrating the immunomodulatory effects
necessary to establish tolerance that would allow a precise
identiﬁcation of speciﬁc probiotics that could overcome the
allergy response has emerged. Additional basic and applied
research is needed to develop avenues of treatment leading to
evidence-based clinical applications.
The Superorganism and the Implications of
Microbiota Research
Clinicians are just beginning to realize the signiﬁcance
of a paradigm shift in biology that has occurred over the past
15 years. Our genetic landscape is inﬁnitely more complex
than hitherto imagined and must be viewed as an ecotope:
human and microbial genomes assemble to interact in an
evolutionarily conserved superorganism in which bacterial
metagenomes and host metabolic networks cooperate toward
the homoeostasis of the consortium.28,29 Sophisticated statis-
tical techniques (bioinformatics) are required to store, manage,
and analyze the enormous amount of information on multi-
level interrelationships (metadata) awaiting biological, physi-
ological, and ecological interpretation and application.30 The
Human Microbiome Project, an international interdisciplinary
effort to “generate resources enabling comprehensive charac-
terization of the human microbiota and analysis of its role in
human health and disease,” highlights the many levels of
complexity of this cutting-edge science.31 As far as clinical
applications are concerned, however, researchers are cautious
in claiming mechanistic insights.32
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Take-home message:
• The assumption that efﬁcacy of supplementation in pre-
vention implies efﬁcacy in therapeutic applications is not
borne out by clinical trial evidence.
• Current clinical science has not identiﬁed agents that are
able to modify host disease phenotype, let alone individ-
ual host response.
• In the context of the superorganism, novel avenues of
research are required before we can claim to have
worked out the mechanisms of disease and treatment
with oral supplementation.
ALLERGY TERMINOLOGY
This review aims to evaluate the possible clinical
beneﬁts of probiotics allergic diseases. For a meaningful
discussion of the effects of supplementation interventions, it
is necessary to deﬁne the endpoints to be evaluated, that is,
allergy, atopy, sensitization, and allergic/atopic diseases.
Allergy
In 2001, a task force within the European Academy of
Allergology and Clinical Immunology (EAACI) proposed a new
nomenclature for allergy,33 and in 2004 a committee of the
World Allergy Organization (WAO) issued a consensus state-
ment on a global allergy nomenclature.34 Only minor changes
were made between 2001 and 2004; most importantly, the mis-
leading term “atopic dermatitis” was replaced by “eczema.”
The basis of the global nomenclature is “hypersensitiv-
ity,” that is, a reaction to a substance tolerated by “normal
individuals.” Hypersensitivity is divided into “nonallergic
hypersensitivity,” in cases when the immune system is not
involved, and “allergic hypersensitivity” or “allergy” when re-
actions occur that involve the immune system or when such
involvement is strongly suspected (Fig. 1). Nonallergic
hypersensitivity reactions are not within the scope of this article.
Allergy can be divided into “immunoglobulin E (IgE)-mediated
allergy” and “non–IgE-mediated allergy.” Non–IgE-mediated
allergic reactions can be mediated via, for example, IgG anti-
bodies, T cells, and even by complement activation, that is, by
Gell and Coombs type II, III and IV mechanisms (Fig. 1).9,10,35
IgE-mediated allergy can be further divided into “atopic
allergy,” induced by allergen-speciﬁc IgE antibodies after expo-
sure to minute amounts (picograms to nanograms) of antigenic
molecules, and “nonatopic type of IgE-mediated allergy,”
which is characterized by IgE production after exposure to high
amounts of allergen (micrograms to milligrams), often bypass-
ing the cutaneous barrier (eg, Hymenoptera venoms or drugs) or
after infestation by helminths (Fig. 1). Nonatopic IgE-mediated
allergy frequently occurs upon repeated exposure.
Atopy
Atopy is deﬁned by a World Allergy Organization
(WAO)/EAACI document as “. a personal or familial ten-
dency, usually in childhood or adolescence, to become sensi-
tized and produce IgE antibodies in response to ordinary
exposure to allergens, usually proteins. As a consequence,
these persons can develop typical symptoms of asthma, rhino-
conjunctivitis, or eczema.” However, not all cases of eczema,
asthma, and rhinoconjunctivitis are due to IgE mechanisms.
When discussing prevention and treatment of allergic
sensitization or IgE-mediated allergic disease in infants, the
deﬁnition may be simpliﬁed to: “Atopy is a tendency in the
infant to become sensitized and produce IgE-antibodies in
response to common allergens, sometimes expressed by devel-
oping symptoms such as asthma, rhinoconjunctivitis, or eczema.”
Atopic sensitization, or the production of allergen-
speciﬁc IgE antibodies, can be documented by in vitro IgE
tests and in vivo tests, most often skin prick tests. However,
different commercial brands of in vitro tests for IgE
FIGURE 1. A general outline of the
subgroups of hypersensitivity.34
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determination do not have the same sensitivity and speciﬁcity.
Commercial tests have also increased their sensitivity over
time. In some cases the allergen source materials bound to the
solid phase have been changed, as have the anti-IgE anti-
bodies for IgE detection. Skin prick tests, however, may yield
different results depending on the technique used and the
potency and composition of the allergen extracts. Thus, these
methods must be deﬁned in context. For comparison of
sensitization between laboratories and within laboratories
over time, the only reliable method is to analyze all samples
by in vitro IgE tests using the same brand and batch of
antigen. Comparison of skin test results are more accurately
made when the same extracts from the same company are
used, although the technique of the clinician is harder to
standardize. Comparisons cannot be made between studies
that use different methods for the estimation of allergen-
specif ic sensitization.
Allergic Diseases
The same principle that applies to the allergy nomencla-
ture may be applied to allergic diseases. Thus, “allergic asthma”
(ie, asthma with a probable or proven immune mechanism) can
be divided into “IgE-mediated asthma” and “non–IgE-mediated
asthma” (Fig. 2). The latter, with cell involvement, should be
distinguished from “nonallergic asthma,” which refers to asth-
matic conditions without involvement of the immune system (if
they exist). Similarly, food allergy should be divided into
“IgE-mediated food allergy” and “non–IgE-mediated food
allergy” (Fig. 3), and eczema should be divided as in Figure 4
These diseases themselves should derive their deﬁnitions from
international documents such as the Global Initiative for
Asthma36 and Allergic Rhinitis and its Impact on Asthma guide-
lines.37 However, it must be stressed that each of these pheno-
typic expressions of disease may have several mechanisms
which, in turn, are likely to correspond at least in part to different
genotypes. Thus, a prerequisite for the evaluation of prevention
and treatment trials is to ensure correct use of the nomenclature
to properly reﬂect the underlying effector mechanisms.
Take-home message:
• In the evaluation of probiotic effect on allergic disease,
the use of a correct terminology is of utmost importance.
• The effects of probiotics can be different in IgE- versus
non–IgE-mediated allergic diseases.
• The possible effect of probiotics may be postulated to
result from either direct immune mechanisms at the level
of the T cell, B cell, or antigen-presenting cell for both
IgE-mediated or non–IgE-mediated allergy (IgG medi-
ated or T-cell mediated)
• Another series of mechanisms is possibly related to the
shock organ, via lymphocyte or mast cell homing mech-
anisms, reduction in sensitivity of mast cells or baso-
phils, or perhaps neural or smooth muscle cells
associated with the skin or mucus membranes.
HYGIENE HYPOTHESIS, MICROBIAL ORIGIN OF
ALLERGIC DISEASE HYPOTHESIS,
AND PROBIOTICS
Allergy is not a single disease, and multiple pathways
are likely involved in both tolerance and sensitization. This
explains why gene and disease linkages are so difﬁcult to
pinpoint. Yet, those studies that have found associations
between gene alleles and allergic disease are limited in their
ﬁndings, possibly due to incomplete deﬁnitions of disease and
health, limitations of single-nucleotide polymorphism selec-
tion, or inappropriate segregation and interpretation.38,39
The “hygiene hypothesis” proposes that, as a result of
modern public health practices, individuals experiencing a rela-
tive deﬁciency in immune stimulation by microbes become
vulnerable to the development of allergic hypersensitivities
and their associated diseases.40 The hypothesis was expanded
FIGURE 3. The nomenclature of food allergy.
FIGURE 4. The nomenclature of dermatitis and its
immunologically mediated forms eczema (immunologically
mediated dermatitis), IgE-mediated eczema (atopic eczema),
and non–IgE-mediated eczema (nonatopic eczema).35FIGURE 2. The nomenclature of asthma.34,35
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when it became clear from studies of transgenic germ-free
animals that the disruption or absence of gut microbiota
accounts for the development of allergic airway responses in
the absence of prior systemic priming.41 As an extension of the
hygiene hypothesis, the “microﬂora hypothesis of allergic dis-
ease” was postulated to highlight the role of the gut in modu-
lating host immunity in early life42 and possibly in later life.43
Cross-sectional and cohort studies in young children with aller-
gic diseases have shown an association between microbial pat-
terns of colonization and allergic disease not displayed by
healthy controls.44 Additionally, an altered pattern of micro-
biota composition in early life, resulting in delayed colonization
associated with the caesarean mode of delivery, has been asso-
ciated with an increased risk of allergic disease.6 High turnover
of Escherichia coli strains in Pakistani children compared with
Swedish children during the ﬁrst 6 months after birth leads to
stronger activation of the intestinal immune system.45 Trans-
location of bacteria also occurs during the initial encounter;
however, once an IgA-speciﬁc response to that strain of bacte-
ria has developed, translocation and immune stimulation
wanes.46 Thus, supplementing with one probiotic strain might
not be effective in modulating the immune response, and con-
sideration should be given to supplementing with repeatedly
changing probiotic strains in early life to maximize the stimu-
lation and maturation of the immune system.
Take-home message:
• Genetics point to a multiple pathway etiology of allergic
disease that has been marginally characterized by current
research.
• The hygiene hypothesis points to individual susceptibil-
ity in certain host–environmental conditions but provides
no quick ﬁxes in either compartment.
• The microﬂora hypothesis of allergy raises the hope of
“educating” host immunity, but research into the normal
and altered microbiota composition is needed for clinical
applications.
PROBIOTICS AND ALLERGIC DISEASE
Establishing the Link Between Probiotic
Administration and Disease Treatment
Deﬁning the diverse composition of microbiota in human
populations is meaningless unless functional links can be made
between identiﬁable microbiota and speciﬁc diseases.47 The pro-
biotic concept has a long history, but progress in the scientiﬁc
and medical evaluation and validation of speciﬁc products has
been slow.48 A possible molecular mechanism for tolerance is
illustrated by recent studies using high-throughput technologies
that suggest the bacterial–host interaction may induce the expan-
sion of T regulatory cells and the expression of immunomodu-
latory cytokines such as interleukin (IL)-10 and transforming
growth factor (TGF-b).49 However, these interactions are very
complex and involve networks of genes, receptors, signaling
molecules, and patterns of disease. Sampling, analysis, and the
evaluation of response to intervention are difﬁcult to carry out,
and sophisticated bioinformatics and systems biology techniques
are needed to interpret the complex interactions and extensive
amount of data generated from a large number of subjects.50–52
Signiﬁcant data and insights have been provided by metagenome
projects undertaken by various centers.31,53 However, to date,
the microbiota associations that have been investigated have
been the result of different methods, tools, and host species,
and as a consequence the results have often been inconsis-
tent.6,54–57 Even so, tantalizing outcomes, particularly in studies
of eczema in at-risk children, continue to fuel an interest in the
ﬁeld.58,59 However, a speciﬁc stimulus originating from, or the
lack of a particular species of, commensal bacteria has not been
demonstrated in this setting.60 Furthermore, these studies have
often been misquoted in the review literature.61 The claim that
probiotics work by sustainably altering the intestinal microbiotic
niches is not easy to demonstrate from a biological point of view
and has not been supported by evidence from human studies. In
clinical trials of probiotic supplementation to achieve tolerance,
candidate probiotics should ideally achieve a degree of individ-
ualization of as-yet unreachable sophistication with respect to the
host and its microbiota. The trials should probably also control
for additional factors such as diet and vaccination schedules,
which will play a role even if the hygiene or microbial origin
hypotheses are correct. Thus, the practice of simply ﬂushing the
ecosystem with a few chosen species of bacteria without tailor-
ing the probiotics to the host will probably be offset by con-
served homoeostatic mechanisms.
Bradford Hill’s criteria for causal inference should apply in
probiotic research: the strength and consistency of association,
temporality, biological gradient, and coherence should be specif-
ically examined.62 However, relying solely on epidemiological
data will not provide all the answers. Although microbiological
methods for studying the microbiota have advanced rapidly
through the use of high-throughput sequencing, there are still
technical challenges that may result in failure to identify whole
bacterial communities that have a substantial effect on health, as
highlighted by oral microbiologists.63 However, recent data from
the Metagenomics of the Human Intestinal Tract (MetaHIT) pro-
ject suggest that it may be possible to deﬁne a limited number of
intestinal symbionts and to carry out investigations to associate
them with disease.64 Generally speaking, the idea that supplemen-
tal probiotic bacteria may be used to manipulate evolutionarily
conserved homoeostatic mechanisms remains a hypothesis.65
Take-home message:
• The mechanisms by which microbial exposure affects
the development and severity of allergic disease needs
to be better understood.
• How networks of genes, receptors, and signaling mole-
cules are involved in host–microbiota interaction pat-
terns remains largely unknown. These networks need
to be linked to disease states.
• Bioinformatics tools are needed to interpret the relation-
ship of the microbiota compartment with these networks.
• How supplementation sustainably modiﬁes the intestinal
ecology remains to be determined for long-term disease
outcomes; identifying individuals or populations likely
to beneﬁt is not currently feasible.
• More stringent causality assessments should be applied
to demonstrate the consistency of an association and
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biological gradient in the assumed linkage between
(undeﬁned) microenvironmental health and allergies.
• Our relationship with our resident microbiota is a highly
conserved species-speciﬁc trait, unlikely to be amenable
to modiﬁcation by easily manipulated homoeostatic
mechanisms.
Mechanisms of Action
We do not yet understand the mechanisms by which
probiotic supplements would be an effective treatment for
allergic disease, and the proof of principle for supplementation
and reliable clinical use is not clearly established. As this vast
area of biomedicine is beyond the scope of the present
overview, we focus brieﬂy on 4 areas in need of more basic
research before clinical applications may be proposed (the
composition of the various microbiota, the gut ecosystem, the
pattern of neonatal colonization, and the complex nexus of
interrelationships known as commensalism), and within each
review the mechanistic rationale for supplementation in the
treatment of allergic disease.
The Composition of the Microbiota
Microbiologists still argue about the extent of our
knowledge regarding what constitutes a “normal” microbiota
and how the microbiota may affect the immune system at differ-
ent stages of development and adulthood.66 Until recently, most
of our microbiological knowledge was derived from cultivable
bacteria, and clinical applications were inferred from quantitative
analysis of the fecal microbiota.67 The recent analysis of the
microbiota from the fecal samples of a few individuals was made
possible by the advent of high-throughput sequencing methods
that make use of ampliﬁcation, cloning, and sequencing of the
16S rRNA genes and revealed a hitherto unseen complexity and
biodiversity. One problem with the high-throughput sequencing,
however, is represented by technical difﬁculties involving ‘uni-
versal” primers and computer software to address a still error-
prone technology, which generates a large amount of data.62 The
advent of metagenomics promises an even greater level of power
and precision by sequencing the complete genome of all bacteria
present in samples taken from the intestinal communities.64
The Gut Ecosystem
The indications for clinical application of probiotics are
even less clear than the normal composition of the microbiota.
As studies of the gut and other microbiota begin to emerge, it is
becoming increasingly clear that closely related species and
even strains can interact very differently with their host habitats
and various disease states.68 Studying optimal composition in
parallel with clinical applications has never been attempted due
to the difﬁculty of deﬁning both healthy microbiology and of
characterizing the fundamental mechanisms underlying pertur-
bations of resident and allochthonous communities (except in
some non–IgE-mediated disease states).54 Human ecological
studies of the biodiversity of the human habitat have revealed,
however, that host immune reactions, disease processes, and
treatment constitute selective hurdles for supplemented bacte-
ria.48 We must also think in terms of the effect of supplemen-
tation beyond the gut environment. This means factoring in the
interrelationships with other bacterial species in ﬂow environ-
ments elsewhere in the host. This higher level of complexity
contributes to making targeted interventions via microbiota
modiﬁcation even more difﬁcult to plan. After all, we are inter-
vening through a single compartment of the host physiology by
supplementing doses of one type of microorganism. To com-
pound the matter, the various habitats within the human host
(such as nose, oropharyngeal cavity, trachea, bronchi, and distal
genitourinary tract) harbor diverse autochthonous microbiota.
These communicate among themselves and with the host
through a steady-state outﬂow of signaling molecules, many
fulﬁlling poorly appreciated immune and metabolic functions
for the host,69 and all contributing to microenvironmental
homoeostasis between host and commensal species.
Neonatal Colonization
When what is known about neonatal colonization is
factored in, more complexity arises. The maternal vaginal and
fecal microbiota, as well as breast milk,70 are the primary sour-
ces of bacteria for colonization and succession in the sterile
neonatal intestine. Because we do not know what constitutes
a “healthy” (infant) microbiota, targeting intervention during
a hypothetical “window of opportunity” for improved or thera-
peutic microbiotal modulation is even more difﬁcult than later
treatment. Furthermore, our preliminary investigations have re-
vealed a complex hierarchy of metabolic or immunological pos-
sibilities due to many novel bilateral genome adaptations.71
External (eg, human, animal, and environmental contact; hospi-
talization; antibiotic use) and dietary (eg, introduction of solids,
fermented foods, live yogurts) factors are likely to inﬂuence the
infant and toddler’s highly variable developing gut ecology with
transients and relative proportions of a wide range of species.72
Commensalism
The epidemiology of bacterial colonization and succes-
sion in the human host remains to be explored, especially
because the role of a bacteria–host dialog involving bacteria-
to-bacteria signaling, bacteria–mucin dynamics,73 and bacte-
ria–enterocyte crosstalk55 is increasingly invoked to unravel
the cellular and molecular complexity these networks dis-
play.53 Clinical applications are still hampered by our limited
understanding of these nested mechanisms.
The appropriate indications, length of treatment, dose,
and species to use to modulate the immune system remain to
be fully elucidated. Thus, to date, clinicians cannot prescribe
with any certainty. Even the selection of desirable bacterial
species is empirical. Despite the lack of solid evidence to
support their clinical use for long-term protection or imme-
diate treatment, the use of probiotics for at least some patients
remains hypothetically valid.
Take-home message:
• Our knowledge of the composition of the autochthonous
microbiota is limited: its variations with development
and aging, in health and disease are poorly known.
• The gut ecosystem is only one human habitat and the
way it is linked to systemic disease is still to be fully
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investigated. Interventions designed to make microor-
ganisms work for us should be ecological.
• To take advantage of the “neonatal window of opportunity”
for intervention, we would need a better understanding of
epigenetics and genomics, both human and microbial.
• We are far from being able to monitor, modulate, or
construct an individual treatment rationale predicated
on the window of opportunity represented by the early
process of microbial colonization.
Three scenarios regarding the fate of probiotic supple-
ments in vivo.
Quality of Clinical Studies
(Evidence-Based Medicine)
Even today, adequate information from which the
consumer and health professional can judge the efﬁcacy and
safety of retailed probiotics is partial or lacking altogether.
More than half of the probiotic papers in the PubMed
database are reviews, not reports of the results of experimen-
tal or medical science. Additional difﬁculties in interpreting
health beneﬁts associated with probiotics include trials that
use experimental preparations instead of actual probiotic
products available to the clinician and variable outcomes
between results from independent trials.
Several randomized clinical trials examining the role
of probiotics in allergic diseases have been published in the
past few years, and the quality of clinical studies on
probiotics has been assessed in several metaanalyses. In
2007, prevention of allergic disease and/or food hypersen-
sitivity outcomes were assessed by 6 studies reporting
a total of 1549 infants.25 Randomization, allocation con-
cealment, and blinding of treatment were judged adequate,
but loss to patient follow-up was considered excessive (17–
61%). Heterogeneity between studies was listed as a bias in
a meta-analysis of 5 studies of probiotics administered to
reduce eczema in a pooled total of 1477 infants. No beneﬁts
were reported for any allergic disease or food hypersensi-
tivity outcome.
Boyle analyzed 12 randomized controlled trials (N ¼
781 children), 11 of which tested Lactobacillus species,
alone or in combination with other probiotics, for the treat-
ment of eczema. The quality of studies varied, and many
failed to adequately report the randomization and blinding
methods used. Five studies compared probiotics with pla-
cebo on their ability to reduce Scoring Atopic Dermatitis
(SCORAD) scores, but none yielded signiﬁcant results.
The same lack of evidence was found when quality of life
was evaluated in 2 studies. The authors concluded that the
heterogeneity between studies may be attributable to pro-
biotic strain-speciﬁc effects.74
Another meta-analysis evaluating the role of pro-
biotics in the treatment of pediatric eczema reported
a signiﬁcant difference in SCORAD in the group using
probiotics, when compared against the placebo group (see
Probiotics and Atopic Eczema). However, the analysis of
the duration of treatment, probiotic strains, and the age of
patients was not able to identify signiﬁcant differences
between the probiotic and the placebo groups.75
A further metaanalysis examined the effect of pro-
biotics on prevention and treatment in pediatric eczema. It
included 21 trials (N ¼ 1898 children) published between
February 1997 and May 2007, with 10 double-blind, random-
ized controlled clinical trials (6 prevention studies [N ¼ 1581]
and 4 treatment trials [N ¼ 299]). These studies supported the
use of probiotics in the prevention of pediatric eczema, but
the clinical signiﬁcance of the treatment effect on SCORAD
reduction was questionable.24
Take-home message:
• The probiotic literature consists mainly of reviews, few
of them systematic. Meta-analyses are rare.
• The results of clinical trials are not reproducible in
everyday clinical practice because the probiotics used
are exclusive to the research setting.
• Issues that have weakened systematization include com-
pliance, comparator deﬁnition, effect of treatment deﬁ-
nition, randomization and blinding, probiotic diversity,
patient heterogeneity, and lack of evidence.
• The quality of the studies varied, but that meta-analyses
were possible is encouraging.
• These biases argue in favor of a “back-to-the-drawing-
board” recommendation for probiotic research.
The gut is a river-like ecology: various niches are occupied in
a ﬂow dynamic model where microbial signaling, antimicro-
bial compound warfare, and horizontal gene transfer are in
a constant ﬂux. “Flushing” such a stable–unstable microenvi-
ronment with billions of colony-forming units of potentially
“alien” bacteria mimics the real-life situations of intake of
food or other substances. This leads to 3 basic explanations
for whydgenerallydnothing much happens to upset the
digestion of the human host:
1. The inﬂux meets the ecological requirements for
acceptance by the resident microbiota: the treatment does
not achieve its purpose because the immune system does
not kick in or is not affected.
2. The inﬂux generates rejection mechanisms from the
resident microbiota because all niches are occupied: the
treatment does not work because of selection pressure
resulting in the probiotic bacteria being “ﬂushed out.”
3. An exchange of genes and niches occurs through quo-
rum sensing and chemical warfare for environmental
homoeostasis, resulting in a beneﬁcial alteration in immune
response. As the default immune response is tolerance, noth-
ing much happens to upset the host daily routine, which may
include the continued expression of an allergy phenotype.
The gut is one of the largest immune organs in the body and is
the seat of the most active homoeostatic mechanisms known to
physiology. Most microbiological events are geared toward the
establishment of an equilibrium between resident and allochth-
onous species and host defenses. These complex biological
mechanisms are evolutionarily conserved and are resistant to
modiﬁcation by relative newcomers on the scene, as studies of
the microbiota increasingly reveal.
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PROBIOTICS AND RESPIRATORY ALLERGY
Asthma
Experiments on mice have demonstrated that anti-
biotics, by altering the intestinal microbiota, enhance allergic
airway responses and that oral probiotics can modulate
allergic responses in the lower respiratory tract.76–78 How-
ever, probiotics as mucosal immune modulators targeting
asthma outcomes or parameters have primarily been used
for prevention purposes through neonatal supplementation.
When administered to adult mice, the supplementation with
some probiotic strains may improve asthma features such as
airway eosinophilia, local cytokine responses, and bronchial
hyperresponsiveness.78,79 It is against this backdrop that some
researchers have explored the potential of probiotic therapy in
human asthma.
A trial of a synbiotic preparation in 1223 pregnant
women with an increased risk for allergy in their offspring
illustrates the difﬁculties of applying the results of studies
from a prevention setting in the context of treatment. The
women received a mixture of 4 probiotics for 4 weeks before
delivery, and their infant received the same probiotics in
combination with a prebiotic for 6 months from birth. The
children were then followed up until their ﬁfth year and
monitored for allergy development. As a secondary outcome
of the study, asthma was observed to develop among 121
children, but no difference in incidence rates was observed
between the groups. However, the conclusions of this trial
appear relevant for prevention and not treatment purposes, as
the main difference was lower rates of allergy among infants
born by caesarean section.80
In a randomized trial, 231 newborns (though not their
mothers) received Lactobacillus acidophilus supplementation
for 6 months. This did not protect them against wheezing
during their ﬁrst year of life.81
In another prevention study, the supplementation of
infants at risk of allergy with Lactobacillus reuterii for 1 year
failed to inﬂuence asthma prevalence rates at 2 years. In this
study carried out in an eczema prevention setting, respiratory
allergy was only a secondary outcome measure.82
In a rare study reporting negative outcomes from
probiotic use, prescribing Lactobacillus rhamnosus GG sup-
plements for 6 months to 105 infants in a primary allergy
prevention setting actually increased the prevalence rate of
recurrent ($5) episodes of wheezing bronchitis among
patients treated with probiotics, but only 17 infants had devel-
oped wheezing and the outcome was not primary.83
In a randomized double-blind trial, an unselected
population of pregnant women was treated with L. rhamnosus
GG, L. acidophilus La-5, and Biﬁdobacterium animalis
subsp. lactis Bb-12 from the 36th week of gestation until 3
months postpartum while breastfeeding. The primary end-
point was atopic disease. Asthma was monitored separately
during the ﬁrst 2 years. However, no signiﬁcant effect of the
intervention emerged during this period.84
Thus, although inhalant allergen sensitization appeared
slightly downmodulated in subgroup analyses of 2 popula-
tions,83,85 neonatal studies do not associate probiotic treatment
with reduced prevalence of inhalant allergen sensitization.85
Supplementation is not without its risks. There is
a documented association between L. rhamnosus GG admin-
istration and cat allergen sensitization.84 The effects on aller-
gic airway symptoms are mixed. Reports of an increased
proportion of children with frequent wheeze during the ﬁrst
2 years of life after perinatal administration of L. rhamnosus
GG have begun to appear,85 similar to ﬁndings in a mouse
model of Lactobacillus casei intervention.86
Clinical treatment trials of probiotics speciﬁcally target-
ing asthma are rare, and relatively short follow-up periods
(usually 1–2 years, sometimes 4–5 years) are a feature of
these studies.
In one study of preschoolers, 187 children aged 2 to 5
years were given fermented milk containing 1010 cfu L. casei,
or placebo, each day for 12 months. There were no statisti-
cally signiﬁcant differences between the groups in terms of
cumulative incidence of asthma episodes.87
Two secondary prevention studies have recently been
published. In the ﬁrst study, 71 infants with atopic eczema
(median age 5 months) were given supplements containing
a synbiotic mixture of Biﬁdobacterium breve M-16V and
a proprietary fructo- and galactooligosaccharide mix or a pla-
cebo for 3 months. At the 1-year follow-up, the prevalence of
frequent wheezing and wheezing and/or noisy breathing apart
from colds was signiﬁcantly lower in the group receiving the
synbiotic (13.9% vs 34.2%, with an absolute risk reduction of
20.3% in favor of the synbiotic). However, these were sec-
ondary ﬁndings in a study targeting patients with eczema for
their respiratory symptoms.88
In the second study of infants at risk of allergic disease,
L. rhamnosus GG 10 was given for 6 months to 131 subjects
aged 6 to 24 months presenting with $2 episodes of wheeze
and a family history of atopic disease. Asthma-related events
(need for inhaled medicine, symptom-free days) and atopic
eczema events were recorded for a 1-year period, during
which no difference in asthma-related events reached statisti-
cal signiﬁcance.89
Among older children and in adolescence or young
adulthood, the efﬁcacy of probiotic supplementation for
respiratory treatment appears to be limited for methodological
considerations.
In a study targeting 6- to 12-year-old children with
asthma and allergic rhinitis, Lactobacillus gasseri A5 supple-
ments were given for 2 months. Pulmonary function and peak
expiratory ﬂow rate increased signiﬁcantly and clinical symp-
tom scores relating to asthma and rhinitis decreased in the
group treated with the probiotic. This study was, however,
limited by its short study duration and small sample size.90
Twenty-nine adult asthmatics with house dust mite
allergy were randomized in a double-blind study to receive
a synbiotic (B. breve M-16V with galacto- and fructooligo-
saccharide) during a single month. The primary outcome was
allergen-induced bronchial inﬂammation. A secondary out-
come, peak expiratory ﬂow, improved signiﬁcantly in the
group receiving the synbiotic.91
In a population of 18 teenagers and young adults who
presented with allergic rhinitis, 7 patients with asthma were
randomly treated with L. rhamnosus GG or placebo for a total
of 4.5 months before, during, and after the birch pollen
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season. There were no signiﬁcant differences between the
prevalence of nose and eye symptoms. The cumulative use
of allergy and asthma drugs increased in the probiotic group
and, compared with baseline, no signiﬁcant differences were
found during the pollen season. Overall, supplementation did
not improve respiratory symptom scores.92
In a 1997 double-blind crossover trial, 15 adults with
moderate asthma were given yogurt with or without L. acid-
ophilus in 2 single-month treatment phases. Similar to the
study with L. rhamnosus GG described above, this study
was not able to match a net beneﬁt of supplementation in terms
of immune parameters (a modest improvement of eosinophilia
and increased interferon gamma expression) with signiﬁcant
differences in peak expiratory ﬂow or spirometry assessment.93
Take-home message:
• Proof of principle for probiotic use in asthma has been
inferred from murine models.
• What we know about probiotics in asthma is derived
from prevention studies.
• No primary prevention study has been able to demon-
strate an effect of probiotic supplementation in asthma in
humans.94
• The quality and power of some studies have been
questioned.82
• There is as yet no evidence that probiotic supplementa-
tion modulates disease phenotype: supplementation is
not therapy.
• Positive studies should be replicated in larger samples
and for a longer period of time.
• Adolescents and young adults may not provide the best
setting for intention-to-treat studies because preexisting
allergen sensitization, atopy phenotype, and stage of
allergic disease may confound treatment efﬁcacy.
Allergic Rhinitis
Epidemiologic evidence indicates that immune responses
in the gut may modulate responses in distant target organs,
including the nose,46 and immune effects beyond the gastroin-
testinal tract have been documented.95 Probiotics have been
shown to alleviate symptoms and to affect markers of allergic
inﬂammation, including a decrease of eosinophil inﬁltration into
the nasal mucosa96; decreasing IL-5 production97; and increas-
ing TNF-a, interferon (IFN)-g, IL-10, IL-12, and IL-13 pro-
duction in adults and children suffering from pollen or dust mite
allergy. These considerations form the tenuous background on
which probiotics, including the Biﬁdobacterium longum BB536,
L. casei Shirota, Lactobacillus paracasei LP33, L. acidophilus
L92, and L. paracasei ST11 strains have been proposed for
treatment of allergic rhinitis.98–103 It is noteworthy that these
data were obtained in experimental settings and that, yet again,
the heterogeneity of reporting precludes meta-analyses.
Perennial Allergic Rhinitis
In children, the use of fermented milk fortiﬁed with
L. paracasei LP33 has been proposed for the treatment of
perennial allergic rhinitis (PAR) and has achieved signiﬁcant
reduction in pediatric rhinitis quality of life.104 In a study of
preschoolers treated with milk fermented with 1010 cfu L. casei
or placebo for 12 months, a difference in the cumulative inci-
dence of rhinitis episodes was found.89 In another study, a small
number of 6- to 12-year-old children who suffered from asthma
and allergic rhinitis were given L. gasseri A5 supplements or
placebo. The rhinitis symptom score decreased in the treated
group.90 Finally, a particular form of PAR was assessed in
nonprofessional marathon runners but L. rhamnosus GG sup-
plementation did not yield a positive effect.104
Seasonal Allergic Rhinitis
Seasonal allergic rhinitis (SAR) may be triggered by the
pollens of numerous plant families, and studies of the effect
of probiotics on SAR have been performed in a series of
models. In a Finnish study testing L. rhamnosus GG versus
placebo for the treatment of birch pollen–induced allergic
rhinitis, no signiﬁcant differences in rhinitis symptom scores
were found.92 In another Finnish study, 47 children with birch
pollen allergy randomly treated with a combination of
L. acidophilus NCFM and Biﬁdobacterium lactis ATCC
SD5219 or placebo experienced a nonsigniﬁcant reduction in
nasal symptoms. This speciﬁc combination of probiotics reduced
pollen-induced inﬁltration of eosinophils into the nasal mucosa.96
A UK study found that L. casei Shirota, administered via a milk
drink for 5 months, signiﬁcantly reduced the levels of antigen-
dependent IL-5, IL-6, and IFN-g in grass pollen–induced rhinitis.
Levels of speciﬁc IgG increased and speciﬁc IgE decreased in the
probiotic group.103 A fourth study, testing an ad hoc mixture of
L. rhamnosus GR-1 and Biﬁdobacterium adolescentis supplied
in a yogurt, found no clinical effect in a group of adult patients
with ragweed-induced allergic rhinitis. However, potential desir-
able effects were found in the cytokine proﬁles of these patients,
albeit without a clinical symptom tie-in.105
Several studies have focused on Japanese cedar pollen
(JCP)-induced allergic rhinitis. Two studies of intervention with
Lactobacillus plantarum 14 (LP14) in female students found
a signiﬁcant improvement in ocular symptom–medication score
that was associated with the inhibition of postexposure eosino-
phil counts.106 A randomized, double-blind placebo-controlled
trial of 44 subjects allergic to Japanese cedar and treated with B.
longum BB536 for 13 weeks during the pollen season found
signiﬁcant decreases in clinical scores in the treated group. These
results were attributed to immunomodulation of a T-helper 2
(Th2)-mediated immune response102 and to a “stabilization” of
ﬂuctuations in the composition of the patients’ fecal microbio-
ta.107,108 In contrast, in this same group, numbers of Bacteroides
fragilis and Bacteroides intestinalis were signiﬁcantly higher
among JCP-allergic patients and correlated positively with
symptom scores and JCP-speciﬁc IgE levels.109
Another double-blind placebo-controlled study exam-
ined the effect of Lactobacillus GG and L. gasseri TMC0356
in the same setting. A yogurt prepared with these bacteria and
administered to 40 subjects with a clinical history of
JCP-allergic disease signiﬁcantly decreased the mean rhinitis
symptom score. These effects were attributed to a speciﬁc
downregulation of the Th2 immune response.99 The results
from this study suggested that stabilization of the intestinal
microbiota by the selected probiotic strains was associated with
these clinical ﬁndings110 and that the diversity of intestinal
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biﬁdobacteria could be a prospective target for using probiotics
in the management of JCP.111
Intriguingly, a recent study showed that recombinant lactic
acid bacteria expressing a major JCP allergen had both allergen-
speciﬁc and non–allergen-speciﬁc clinical effectiveness. These
bacteria suppressed the allergen-speciﬁc IgE response and nasal
symptoms in a murine model of cedar pollinosis.112
Despite these enthusiastic reports, it should be noted that
in many studies the primary clinical outcome was negative, and
the quality of design has been judged as poor. A speciﬁc
mechanism linking intestinal effects with an antiinﬂammatory
or immunosuppressive effect on the local upper respiratory tract
has yet to be deﬁned, and such a mechanism is needed to
provide us with the grounds for their clinical use. Unlike in
other clinical ﬁelds, in rhinitis, the effect of probiotics has
primarily been demonstrated for treatment, whereas their
beneﬁts for prevention remain inconclusive.
Take-home message:
• The clinical use of probiotics in allergic rhinitis are based
on postulated effects beyond the gastrointestinal tract.
• The literature suggests that the disease may be subdi-
vided into several phenotypes (PAR, SAR, JCP
induced). This can be misleading in investigating treat-
ment effects in pollinosis.
• The heterogeneity of studies precludes meta-analysis.
PROBIOTICS AND FOOD ALLERGY
Very few studies have explored probiotic therapy for
food allergy, and no systematic review seems possible
currently. Furthermore, the clinical information regarding pro-
biotics and food allergy is derived from studies of patients with
eczema who may represent a speciﬁc phenotype of disease.
Proof of principle in humans is thus lacking from population
studies. A narrative summary of ﬁndings from selected studies
follows, but no recommendation for the use of probiotic therapy
in this clinical setting may currently be extrapolated.
Studies reporting beneficial
therapeutic effects
In 1997, a group of infants with cow’s milk allergy,
atopic eczema treated topically, and a positive family history
of food allergy were randomized to receive an extensively
hydrolyzed formula with or without Lactobacillus GG to alle-
viate their skin and food allergy symptoms. The primary objec-
tive was to reduce inﬂammation in the setting of a cow’s milk
elimination diet. A single month of treatment with the probiotic
was followed by 1 month with the hydrolysate. The patients
were then reexamined and orally challenged with cow’s milk.
The atopic eczema score markedly improved in the active treat-
ment arm of the study (from 26 down to 15), but not among
untreated patients. It also improved (from 26 to 11) in a group
of infants who were breastfed while their mothers received
Lactobacillus GG for 1 month. However, there was no effect
of supplementation on cow’s milk allergy symptoms.113
In a subsequent study, the same researchers fed an
extensively hydrolyzed formula with or without Lactobacillus
GG and Biﬁdobacterius lactis Bb-12 to infants who had
developed atopic eczema although exclusively breastfed.
There was a signiﬁcant improvement in atopic eczema in
the 9 infants who had received probiotic supplementation,
but only in 4 of 9 controls.114 Again, no effect was reported
on food allergy. A similar lack of effect of probiotic supple-
mentation was noted using a combination of L. rhamnosus
and L. reuteri.115 However, another study reported a beneﬁcial
effect of L. rhamnosus GG but not of a mixture of B. breve,
Propionibacterium freudenreichii, and Propionibacterium IS.116
What emerges from these studies is that probiotic supple-
ments are reported to be effective in the prevention of eczema
while proof of clinical efﬁcacy in food allergy is still lacking.
Studies reporting no beneficial
therapeutic effects
A study of infants with atopic eczema concluded that there
was no beneﬁt of adding L. rhamnosus or L. rhamnosus GG to
an extensively hydrolyzed formula. Neither was there a signiﬁ-
cant difference in allergy (total and speciﬁc IgE), inﬂammatory
markers, or cytokine production by peripheral blood mononu-
clear cells after supplementation.117 Another study showed no
therapeutic advantage of L. rhamnosus GG over placebo for
atopic eczema in infants with food allergy.118 In a group of
children with eczema younger than 10 years of age, the daily
intake of a mixture of L. rhamnosus and B. lactis for 12 weeks
did not differ from placebo in improving atopic dermatitis.119
Nevertheless, a signiﬁcantly greater improvement was noted in
food-sensitized compared with non–food-sensitized patients, but
the observed improvement was not sustained 4 weeks after ces-
sation of probiotics. Similarly, young infants with milk allergy
treated with an extensively hydrolyzed formula supplemented
with placebo or with L. casei and B. lactis did not display differ-
ences in tolerance to cow’s milk at 6 and 12 months.120
Studies reporting no beneficial
preventive effects
In an Australian study, 218 infants whose mothers were
atopic were randomized to receive, from birth until 6 months of
age, either a placebo or 3 · 109 cfu L. acidophilus daily. By 6
months and 12 months of age, the incidence of atopic eczema in
the Lactobacillus group was similar to that in the placebo group.
Surprisingly, the probiotic group had a higher frequency of pos-
itive skin tests to common foods and aeroallergens than the
placebo group (40% vs 24%).81 A Finnish study reported the
effects of administering, for 2 to 4 weeks before delivery, a
mixture of 4 probiotics (two Lactobacillus rhamnosus strains,
Biﬁdobacterium spp, and Propionibacterium spp) to women
pregnant with infants at high risk of atopy. The infants were then
given a placebo or the probiotic mixture plus a prebiotic for 6
months.121 By 2 years of age, the 2 groups showed no signiﬁcant
difference in the cumulative incidence of any allergic disease or
sensitization to food allergens. Another Australian study found
a similar lack of treatment effect in the rate of development of
allergy or of IgE sensitization by 5 years of age in children whose
mothers had received a probiotic mixture during the last month of
pregnancy and who had received the same probiotics for the ﬁrst
6 months of life.83 Probiotic intake was associated with a signif-
icant reduction in allergy incidence (24.3% vs 40.5% in those
who received placebo) when birth by caesarean section was
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considered.80 Similar ﬁndings have been reported by others.85,122
A study of 3 European birth cohorts has shown no relationship
between the development of atopic eczema or food sensitization60
and the type of intestinal commensal bacteria; this is in contrast to
most observational studies of intestinal microbiota composition
and eczema/atopy in infancy.60
The Diagnosis and Rationale for Action Against Cow’s
Milk Allergy123 and National Institute of Allergy and Infectious
Diseases (NIAID) Guidelines124 do not recommend the use of
probiotics for milk or food allergy. However, the NIAID Guide-
lines suggest that in the prenatal and early neonatal periods,
probiotics may be associated with a slight reduction in the inci-
dence of eczema. The most signiﬁcant results were seen when
probiotics were used in conjunction with breastfeeding or a hypo-
allergenic formula. So far, studies have yielded inconsistent ﬁnd-
ings on the usefulness of probiotics in food allergy. The
discrepancies may be attributed to variation among studies in
multiple factors related to the probiotics (type, dose, mixtures,
and duration) or to the recipient (birth method, type of feeding,
and age). The available ﬁndings suggest that there is greater
potential for prevention than for therapy. More studies are
needed to delineate the role of probiotics in allergy practice.125
Take-home message:
• The lack of effect of probiotic treatment in the setting of
food allergy is not related to the lack of evidence of its
effect in the general context of prevention through
immunomodulation.
• Probiotic treatment studies have suffered (being dietary
interventions) from coadministration with adjuvant ther-
apy (prebiotics or synbiotics)
• Failing to make a distinction between maternal treatment
and fetal/neonatal treatment in intervention studies has
reduced the generalization of ﬁndings
• It is likely that food allergy treatment cannot be entirely
dependent on environmental or dietary factors.
PROBIOTICS AND ATOPIC ECZEMA
There is a considerable body of literature published to
date, with at least 14 randomized controlled trials for treating
eczema with probiotics and 14 for preventing eczema in
humans. Unfortunately, these studies are often misquoted,67
and attempts at systematization have been thwarted by the
heterogeneity of probiotic products, study protocols, and
allergy markers used in analyses of the immune modulation
induced by probiotics. The issue of which probiotic is used is
inconsequential. It has been known for some time that indi-
vidual strains pulse dendritic cell activation differently. Thus,
the cytokine proﬁle emerging in response to treatment is sub-
stantially altered, thereby confounding clinical interpreta-
tion.126 Critical to the endorsement of treatment with
supplemented probiotics are 2 of the most quoted studies in
the prevention literature, from which much of the rationale for
treatment is derived. Both studies used the same microorgan-
ism and similar protocols, but achieved diametrically opposite
eczema outcomes: one claimed to show efﬁcacy, whereas the
other showed a lack of clinical effects.20,88
In the treatment of eczema, most studies have tested Lac-
tobacillus species, either alone or in combination with other
probiotics and/or prebiotics. One proof-of-principle study specif-
ically targeted adults.127 Systematic review and/or meta-analysis
of 12 of the 14 published studies have been undertaken by 3
separate groups [see Quality of Clinical Studies (Evidence-
Based Medicine)]. A Cochrane systematic review and one other
meta-analysis found no evidence that probiotics are effective for
treating eczema, albeit with signiﬁcant heterogeneity between
the outcomes of different studies.25,26 A third meta-analysis
found a statistically signiﬁcant effect of probiotic treatment on
the mean change in SCORAD index from baseline to the end of
treatment [mean difference between groups –3.01 points; 95%
conﬁdence interval (CI), –5.36 to –0.66; P ¼ 0.01]; however,
this effect size is of limited clinical signiﬁcance.81
All but one preventive study evaluated lactobacilli (7 used
Lactobacillus rhamnosus strain GG), either alone or in combina-
tion with other probiotics and/or prebiotics.64,65,89–91,114,120,128–134
At least 10 studies limited recruitment to women carrying
a fetus at high inherited risk of allergic disease. However, the
studies were heterogeneous in other respects, particularly in the
timing of the intervention. In 10 studies, treatment was started
during pregnancy, in one during the ﬁrst trimester, and in the
others in the last trimester. In 3 of the last trimester interventions,
maternal treatment stopped with delivery, and in 7 it was contin-
ued for some time during breastfeeding. In 10 studies, a probiotic
was given directly to all infants during the postnatal period,
usually commencing early, but in 3 studies administration started
after 3 months. Treatment ceased within the ﬁrst year in almost
all studies, except for one study, which continued for 2 years. No
study replicated the design and intervention of a previous success-
ful prevention trial, with the exception of the study by Kopp and
colleagues, which yielded different ﬁndings to the similarly
designed study by Kalliomaki et al.64,90 With these caveats
in mind, a number of authors have undertaken systematic reviews
and/or meta-analyses of the randomized controlled trials evaluat-
ing the probiotic effect in eczema prevention. Two meta-analyses
have found no evidence that probiotics prevent the development
of atopy. A Cochrane systematic review included 5 of the 14
trials in meta-analysis, ﬁnding a relative risk of 0.82 (95% CI,
0.70–0.95) attributable to probiotic treatment.26 A more recent
meta-analysis that included 12 of the 14 trials similarly found
a relative risk of 0.79 (95% CI, 0.67–0.92).24 Neither meta-
analysis found evidence that probiotics can prevent the develop-
ment of atopy. There was signiﬁcant heterogeneity in study out-
comes in these meta-analyses (I2, 64 and 31%). Subgroup
analysis suggested that infant treatment without maternal treat-
ment may be ineffective.24 The authors of the Cochrane review
advised caution in interpreting the results of their meta-analysis,
due to heterogeneity and high rates of loss to follow–up
(17–61%) in the individual trials.26
Take-home message:
• There is currently no meta-analytic evidence that probiot-
ics are clinically effective for treating established eczema.
• The possibility that novel probiotic strains or treatment dur-
ing adulthood may prove effective cannot be discounted.
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• Further research into probiotic design and/or patient indi-
cation is warranted.
• Drawing inferences for therapy from prevention studies
may be misleading.
• Meta-analytic evidence suggests probiotics may be
effective for preventing eczema, but due to heterogeneity
in study designs and outcomes it is impossible to issue
clear recommendations at present.
• Further basic research into probiotics should address the
question of the optimal mode of administration.
• The lack of clear mechanisms of action (intestinal barrier
function and systemic immunity in particular) in the
context of the developing infant intestine prevents opti-
mizing interventions.135
• It is unclear how probiotics exert their effect on the
various pathogenetic aspect(s) of eczema, if at all.
PROBIOTICS AND ALLERGIC
GASTROINTESTINAL DISEASE
Gastrointestinal food allergy may present as a range of
clinical syndromes in infants and young children. The 3 main
gastrointestinal allergic manifestations are food protein–
induced proctocolitis, food protein–induced enteropathy,
and food protein–induced enterocolitis syndrome.118 Eosino-
philic esophagitis has recently been identiﬁed as another con-
dition closely related to food allergy, particularly in
children.136 Symptoms of gastrointestinal food allergy
include persistent diarrhea, rectal bleeding, vomiting, failure
to thrive, irritable behavior, and feeding difﬁculties.137,138
These conditions are caused by non–IgE-mediated mecha-
nisms and are generally characterized by noninfective gastro-
intestinal inﬂammation with an increase in mucosal T
lymphocytes, eosinophils, mast cells, or basophils. However,
these allergic manifestations provide a paradigm of how
interventions may be designed and carried out.
Probiotic effects are thought to depend on innate
mechanisms of immunity via Toll-like receptors, which
promote Th1 cell differentiation; the production of regulatory
cytokines (IL-10 and TGF-b); and an enhanced intestinal IgA
response.139,140 The use of probiotics for the treatment or
prevention of gastrointestinal conditions therefore appears
plausible, although no direct supportive evidence regarding
gastrointestinal food allergy or eosinophilic esophagitis is
available at present. Importantly, animal models on the effects
of various lactobacilli and biﬁdobacteria suggest that there
may be signiﬁcant strain-speciﬁc differences as to how pro-
biotics affect innate and adaptive immune responses.141
The integrity of the epithelial barrier function in the gut is
a key factor in preventing gastrointestinal inﬂammation and
maintaining gut health. Impaired barrier function may lead to
inﬂammatory gastrointestinal conditions, including inﬂamma-
tory bowel disease or celiac disease, and delay the recovery
from infective gastroenteritis.142 Probiotic treatment has been
advocated to improve or maintain barrier function by regulating
epithelial tight junctions.143 However, research has yet to ascer-
tain whether these effects result directly from the probiotic used
or from increased selective pressure among the resident micro-
biota. Although, in theory, probiotic bacteria could reduce the
risk of food protein–induced gastrointestinal manifestations,
this has never been demonstrated in clinical trials.
Probiotic treatment has been attempted for a range of
gastrointestinal conditions, including viral gastroenteritis,144
infantile colic,145 and necrotizing enterocolitis of premature
infants,146 with mixed results. However, the potential for these
interventions has not been prospectively studied in humans.
In summary, there are to date no data speciﬁcally
assessing the effects of probiotics on gastrointestinal food
allergy.119,147 Randomized clinical trials are therefore
required before the use of speciﬁc probiotic strains may be
recommended for the prevention or treatment of gastrointes-
tinal food allergy.
Take-home message:
• Currently there are no data speciﬁcally assessing the
effects of probiotics on gastrointestinal food allergy.
• Randomized clinical trials are required in the setting of
gastrointestinal non–IgE-mediated food allergy.
SOME SAFETY ASPECTS OF PROBIOTICS FOR
ALLERGY TREATMENT
A major theoretical risk from the use of probiotics in the
treatment of allergy is that the documented beneﬁts in a small
number of allergic conditions will not be borne out by strong
evidence of efﬁcacy. Their wide use is due, in part, to the belief
that a bewildering range of allergic symptoms and conditions
may be improved through probiotic consumption. However,
problems linked to the clinical use of novel probiotics without
a long history of safe use are bound to occur when products
derived from nonhuman strains or from the gut microbiota of
healthy humans are used in a community setting.
Species in Lactobacillus and Biﬁdobacterium, the genera
to which most probiotic supplements belong, are generally con-
sidered to be safe as food additives.148–150 Lactobacillus species,
however, have been identiﬁed as cariogenic.151–153 Lactobacil-
lemia (or Lactobacillus bacteremia) is a recognized entity that
has been implicated in infective endocarditis154,155 and the
aggregative potential of the genus has been characterized.156
Experimentally, the intraperitoneal injection of group B L. casei
cell walls produces an inﬂammatory coronary arteritis in mice
that mimics the arterial damage found in children with Kawasaki
disease.157 Dietary supplements are not regulated for purity and
potency, as pharmaceuticals or biological agents are, and thus
the various regimens in which probiotics are used in allergy
treatment have not been tested in exactly the same conditions.
Adverse symptoms or severe systemic disease cannot be corre-
lated in the absence of extensive preclinical studies. Nowhere is
this lack more acutely felt than in the case of enteral feeding
formula, where genera containing many pathogenic species and
strains are used without excluding the possibility that during
mixing and preparation harmful interactions could occur
between the probiotic and the formula.158
The criteria for probiotic product safety are industry
standards, but problems remain, and one national survey
documented the presence of undeclared species or taxonom-
ically incorrect or ﬁctitious microbial names in 51% of the
products it sampled. One preparation contained numerous
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spores with a content of 4.5 · 106 cfu/g Bacillus cereus and 3
others had 8 · 105 to 6 · 106 cfu/g Bacillus subtilis spores.159
The only common side effects associated with probiotic
supplementation are transient gastrointestinal symptoms (such as
nonfunctional bloating and ﬂatulence) attributed to a “die-off”
effect160 of bacterial interference during prophylactic treat-
ment.161 This illustrates an underlying concern of probiotic
research that supplementation with allochthonous microorgan-
isms may cause the adverse effects they are supposed to ﬁght,
given the unknowns of therapy aimed at immunomodulation.162
The very properties for which probiotics have been
proposed for therapy in clinical practice, however, could
easily become a double-edged sword in the allergist’s arma-
mentarium. Skewing the Th1/Th2 balance toward Th1 may
not be always safe, even in healthy individuals. In pregnancy,
for instance, a bias toward the Th2 phenotype is held to be
important to maternal–fetal immune tolerance.163 Stimulation
of Th1 immunity would also not be recommended in patients
with autoimmune diseases that are mediated by a Th1 cyto-
kine proﬁle, especially early in the course of disease.164
In immunocompromised hosts, in addition, lactic acid
bacteria have been involved in human disease. This assumes
importance in the context of widespread administration in
neonatal cohorts, as in the case when probiotics are included
in starting formulae.
Safety concerns, therefore, have always been part of
probiotic research, and are carefully considered by the industry
during the process of probiotic bacterial strain selection.165
Despite these hypothetical caveats, however, the safety of pro-
biotic products in clinical practice remains limited by the
absence of clinical trial evidence rather than by demonstration.
This may be attributed to an overestimation of efﬁcacy outside
research settings or to the lack of well-designed clinical trials
reporting on safety considerations.166
Even the immune safety of probiotics should not be
taken for granted, as reports of sensitization and anaphylaxis
to probiotic supplements have begun to appear, and 3 articles
have reported a total of 99 cases.167–169
In the course of investigating the immunomodulatory
effects of probiotic bacterial strains, researchers found a novel
bacterial strain that suppressed the induction of oral tolerance.
Although Lactococcus lactis BB356 increased antigen-spe-
ciﬁc IFN-g production, it decreased antigen-speciﬁc IL-4
and IL-10 in rodents.170
In conclusion, the theoretical risks outlined here are all
contingent on the yet-to-be demonstrated consistent systemic
inﬂuence of supplements to harness the power of the healthy
microﬂora. Similarly, emphasizing the inevitable downside of
biotherapeuticals in widespread use can only add evidence of
indications where they may be safely and reliably used.97
Take-home message:
• Lactobacilli and biﬁdobacteria are generally considered
safe.
• Episodically, concerns have been expressed over the
possible cariogenicity of lactobacilli and the contribution
of Lactobacillus to bacteremia in infective endocarditis
and experimental Kawasaki disease.
• Safety issues are of utmost importance when probiotics are
added to cow’s milk formulae intended for general use.
• Immunocompromised hosts can be subject to probiotic-
induced bacteremia.
STRUCTURE AND CORRESPONDENCE OF
CLAIMS WITH THE STATE OF THE ART IN
ALLERGY RESEARCH
Regulators have attempted to clarify for the consumer
the possible antiallergic properties of probiotics. To ﬁll an
earlier vacuum, an international consensus on methodology to
assess the efﬁciency and safety of probiotics was issued by
both the United Nations Food and Agriculture Organization
(FAO) and the WHO. These “Guidelines for the Evaluation of
Probiotics in Food” concluded that: “the health beneﬁts for
which probiotics can be applied include conditions such as.
allergy.”22 However, the sentence was deleted in the FAO/
WHO 2002 guidelines.171 The recommendations as set out in
the later report formed the basis for further regulatory actions
by the US Food and Drug Administration and, lately, by the
European Food Safety Administration (EFSA). In 2010, EF-
SA published a “Scientiﬁc Opinion on the Substantiation of
Health Claims Related to Various Food(s)/Food Constituent
(s) Claiming ‘Healthy and Balanced Digestive System’,
Increasing Numbers of Gastro-Intestinal Microorganisms
and Decreasing Potentially Pathogenic Gastrointestinal
Microorganisms Pursuant to Article 13 of Regulation (EC)
No 1924/20061.”172 Allergy was not even an issue examined.
In the 10 years since the publication of the WHO
guidelines, their recommendations have seldom been quoted.
In particular, the criteria for claims that remain outstanding are
rarely the objects of probiotic literature: safety, structure, and
function of “allergy improvement’ claims; generic and product-
speciﬁc claims; and product efﬁcacy and effectiveness remain
poorly investigated areas. Claims made in probiotic research are
not supported by an evidence-based medicine approach. The
measurement of, and criteria for, health beneﬁts and the bio-
markers to be selected are not yet universally accepted. General
criteria, surrogate endpoints, biomarkers of efﬁcacy in allergy
treatment, research needs, and validation of studies are in need
of further investigation from a methodological point of view.
SUGGESTIONS FOR FUTURE STUDIES
The balance of evidence from the present overview
suggests that probiotic supplements do not have a promising
future for the prevention or treatment of eczema, allergic
rhinitis, or food allergy. Extensive further research in several
ﬁelds of biology, microbiology, immunology, allergy, and
related ﬁelds is needed to clarify these issues.
Current research suggests that the future lies in a multidis-
ciplinary approach to basic research and clinical disciplines in
a metascience that does not yet exist. Although the claim that we
are able to tailor interventions to modulate the immunobiology
of human allergic disease through probiotic supplementation
currently belongs to empiricism, nonetheless it has made it into
scientiﬁc journals; hence the need for this overview.
Too many unknowns remain even to decide whether
immune parameters deﬁning phenotypic features for some
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patients may be improved by supplementation. First of all, there
is a need to understand the inﬂuence of diet and other
environmental factors on the microbiota of pregnant or lactating
mothers and their infants through observational studies of
populations with different dietary and environmental exposures.
We need to identify causal pathways and biomarkers (ie,
cytokines and their associated phenotypes) for the health beneﬁts
of probiotics in relation to allergic disease. The ﬁrst steps in this
direction may be to understand whether probiotics for eczema
prevention act through modulation of breast milk immune
modulators (antibodies, cytokines, and growth factors) or
microbial composition, through the induction of low-grade
inﬂammation when directly administered to infants, through
effects on infant intestinal epithelial barrier function, or via other
mechanisms. Effort should be made to deﬁne the populations of
subjects who beneﬁt most from these interventions. Animal
models may provide clues to mechanisms of tolerance.
However, recent data demonstrate that colonic bacteria resident
in other mammals differ from those typically found in humans.
Therefore, caution should be exercised in predicting results in
humans on the basis of animal testing. Among other critical
research issues, the following appear to be topical.
Basic Probiotic Science
1. Are behavioral changes related to hygiene and avoid-
ance of microbes (birthing and nursing conditions, water
and food sanitation, and cleaning practices) responsible
for changes in the establishment of microbial symbioses
that reduce tolerance?
2. What is “dysbiosis” and how does it relate to clinical
phenotype? Population and genetic studies are needed to
answer this question.
3. What is the role of antibiotics, and physicians’ antibiotic
prescribing behavior, in the current spate of allergic
manifestations attributed to “dysbiosis”?
4. What is the composition of the human microbiota in
various environments throughout life, in health and dis-
ease, and particularly in allergic manifestations? Epide-
miological studies are also needed before we can reliably
modify the human microbiota for therapy or prevention.
5. What microbial species and strains are tolerogenic or
induce regulatory immune factors? How does this vary
between subjects in the population?
6. What organs, tissues (in the host compartment), niches, and
populations of microorganisms (in the microbiota compart-
ment) are involved in the induction of tolerance: is it the
oral cavity, the small intestine, or the colon? At ﬁner anat-
omy, is it the epithelium, lymphatic organs, dendritic cells,
mast cells, B cells, macrophages, T cells, or others that is
the primary site from which this activity originates?
7. Is the same site and mechanism as important for early
onset of tolerance as for late onset of tolerance or for
maintenance of tolerance?
8. What is the link between bacteria, the gut and lung
mucosa, the immune system, and the allergic disease
states mediated by mucosal bacterial species?
Probiotic Products for Allergy Treatment
9. Could it be that we do not have sufﬁcient probiotic
strains? Do we need to focus on certain species, such
as L. rhamnosus, which has produced tantalizing out-
comes with regard to eczema prevention? Or should
there be an effort to identify other microorganisms?
Should we try commensals or newcomers?
10. What clinical evidence or markers of disease do we need
to establish to determine whether a well-deﬁned probi-
otic strain is sufﬁcient to modulate host and/or microbial
homoeostasis and to do so efﬁciently? Tolerance is our
immunological “default mode,” but what cytokine pro-
ﬁle or signaling format do we set to deﬁne the success or
failure of an intervention?
11. Do probiotics provide a necessary or sufﬁcient condition
for the establishment of tolerance to antigens? Does the
prevention of allergy through tolerance or treatment
depend on the concurrent administration of probiotic
and antigen?
Methodological Issues
12. Why have well-designed and sufﬁciently powered
longitudinal, multicenter, birth cohort studies and
long-term follow-up studies of randomized placebo-
controlled trials failed to convince their skeptics?
13. Basic research into commensals at the microbiota–human
interface is needed to test the hypothesis that dietary
manipulation via supplementation can affect host
homoeostasis, metagenome interchanges, and modula-
tion, together with their downstream effects. This is
a whole new ﬁeld of enquiry and will require many years
of multidisciplinary research leading to meta-analyses to
identify and validate clinical applications.
14. From a methodological point of view, research should
prioritize long-term, sufﬁciently powered, well-controlled,
randomized, multicenter clinical trials in selected and
unselected human subjects recruited according to current
deﬁnitions. Researchers should adopt research standards
recommended by learned societies in their ﬁeld to facili-
tate future meta-analyses by generating homogeneous
databases.
15. Translational research synthesizing the in vitro and
ex vivo literature is needed before probiotic supple-
ments may become an independent class of
bacteriotherapeuticals.
16. From a regulatory point of view, the transition from
functional food supplement to mucosal immune modu-
lator targeting allergy outcomes should follow estab-
lished practices and should be submitted to scientiﬁc
society and government agency oversight to end the
“probiotic privilege” before claims can be researched
in the context of allergy outcomes.
Clinical Issues
17. Clinical researchers have emphasized the inconsisten-
cies of many probiotic studies in the treatment of
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allergy, and clinical practice studies have identiﬁed the
following as the main confounders of this ﬁeld and,
therefore, possible areas of focus for research173:
deﬁned species and speciﬁc strain of probiotic, the dose
used, the use of combination versus single type, the
method of administration, the age at administration for
prevention, the time after disease onset for treatment, the
duration of therapy, the coexistence of food allergy,
dietary elimination issues, and the limiting of probiotic
feeding to a hypoallergenic formula.
18. The potential side effects of therapy in various allergy
settings should also be the focus of research.
THE FINAL TAKE-HOME MESSAGES
In the consensus opinion of the panel members of the
Special Committee on Food Allergy, the full implications of
probiotic supplementation for the treatment of allergic disease
remain to be worked out; clearly, probiotics are not for
everyone. Even if the hygiene hypothesis and the “microﬂora”
hypothesis of the origin of allergic disease are eventually proved
through biological breakthroughs, it remains to be demonstrated
whether we may stably modulate the host compartment of the
commensal relationship with our resident microbiota. This
needs to be demonstrated at the microbiological, immunologi-
cal, and genetic levels for bacteriotherapeuticals to be accepted
by allergists and clinical immunologists in their daily practice.
This is not to say that the “probiotic hypothesis” for
allergy treatment is a dead end. On the contrary, there is
tantalizing evidence in vitro and in animal models that the
future lies in this direction, that is, that one day we will be
able to orchestrate research efforts toward making probiotics
the agents or adjuvants we need to harness the power of the
microbiota to shift for designated patient proﬁles.
So far, there is no consensus on compartmental
dysbiosis and homoeostasis, and thus the jury is still out on
whether supplementation is the best intervention to achieve
this research objective. A leitmotiv of probiotic research is to
present immune modulation by means of probiotics as a fait
accompli. We contend just as empirically that, given the
weakness of the clinical evidence, probiotic dietary supple-
ments may not be every patient’s cup of tea.
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